Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis-Reference-Cited by-同舟云学术

Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis

Published:2024-03-05 Issue:2 Volume:205 Page:403-411
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Sun Hongxia^ORCID,Kang Eun Young,Chen Hui^ORCID,Sweeney Keith J.^ORCID,Suchko Michael^ORCID,Wu Yun,Wen Jianguo,Krishnamurthy Savitri,Albarracin Constance T.^ORCID,Ding Qing-Qing,Foo Wai Chin,Sahin Aysegul A.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07256-3.pdf

Reference29 articles.

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182. https://doi.org/10.1126/science.3798106

2. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120–1128. https://doi.org/10.1200/JCO.1989.7.8.1120

3. Park JW, Neve RM, Szollosi J, Benz CC (2008) Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8:392–401. https://doi.org/10.3816/CBC.2008.n.047

4. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4–13. https://doi.org/10.3121/cmr.2009.825

5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Noron L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. https://doi.org/10.1056/NEJM200103153441101